Research & Literature

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, et al.

Thyroid : official journal of the American Thyroid Association 2016; (26(1)):1-133 doi:10.1089/thy.2015.0020.

Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.

Do Cao C, Wémeau JL

Annales d'endocrinologie 2015; (76(1 Suppl 1)):1S47-52.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, et al.

The Lancet. Oncology 2016; (17(9)):1272-82.

The History of the Follicular Variant of Papillary Thyroid Carcinoma.

Tallini G, Tuttle RM, Ghossein RA

The Journal of clinical endocrinology and metabolism 2017; (102(1)):15-22 doi:10.1210/jc.2016-2976.

Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.

Sung TY, Jeon MJ, Lee YH, et al.

The Journal of clinical endocrinology and metabolism 2017; (102(3)):793-800 doi:10.1210/jc.2016-2666.

Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma.

Tarasova VD, Tuttle RM

Clinical oncology (Royal College of Radiologists (Great Britain)) 2017; (29(5)):290-297 doi:10.1016/j.clon.2016.12.009.

Response to therapy of papillary thyroid cancer of known BRAF status.

Kowalska A, Walczyk A, Kowalik A, et al.

Clinical endocrinology 2017; (87(6)):815-824 doi:10.1111/cen.13423.

Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.

Vuong HG, Altibi AM, Duong UN, et al.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; (39(10)):1010428317713913 doi:10.1177/1010428317713913.

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.

Verburg FA, Mäder U, Luster M, Reiners C

Clinical endocrinology 2018; (88(6)):950-956 doi:10.1111/cen.13597.

High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.

Gray KD, Bannani S, Caillard C, et al.

Surgery 2019; (165(1)):37-43 doi:10.1016/j.surg.2018.04.059.

Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma.

Kim K, Kim WW, Choi JB, et al.

Annals of surgical treatment and research 2018; (95(4)):222-229 doi:10.4174/astr.2018.95.4.222.

Thyroid Hormone Suppression Therapy.

Biondi B, Cooper DS

Endocrinology and metabolism clinics of North America 2019; (48(1)):227-237 doi:10.1016/j.ecl.2018.10.008.

Dynamic risk assessment in patients with differentiated thyroid cancer.

Pitoia F, Jerkovich F

Endocrine-related cancer 2019; (26(10)):R553-R566.

Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.

Trimboli P, Piccardo A, Signore A, et al.

Thyroid : official journal of the American Thyroid Association 2020; (30(5)):713-719 doi:10.1089/thy.2019.0688.

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity.

Zajkowska K, Kopczyński J, Góźdź S, Kowalska A

Endocrine connections 2020; (9(3)):R47-R58 doi:10.1530/EC-19-0566.

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features and the risk of malignancy in The Bethesda System for the Reporting of Thyroid Cytopathology.

Elliott Range D, Jiang XS

Diagnostic cytopathology 2020; (48(6)):531-537 doi:10.1002/dc.24405.

Prediction mode of more than 5 central lymph nodes metastases in clinically node-negative ipsilateral papillary thyroid carcinoma with tumor size 1 to 4 cm.

Jin L, Sun HL, Zhou L, et al.

Medicine 2020; (99(16)):e19809 doi:10.1097/MD.0000000000019809.

Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a 13-year retrospective review at Jordan University Hospital.

Zurikat RO, Khader M, Azzam MI, et al.

Endocrine 2020; (69(2)):339-346 doi:10.1007/s12020-020-02299-0.

Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

Kim K, Kim JK, Lee CR, et al.

Therapeutic advances in endocrinology and metabolism 2020; (11()):2042018820921019 doi:10.1177/2042018820921019.

Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.

Kim Y, Roh JL, Song D, et al.

Journal of surgical oncology 2020; (122(5)):906-913 doi:10.1002/jso.26090.

Additional Surgery for Occult Risk Factors After Lobectomy in Solitary Thyroid Nodules is Predicted by Cytopathology Classification and Tumor Size.

Flagg A, Rooper L, Sheth S, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(7)):754-760 doi:10.4158/EP-2019-0473.

A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.

Romei C, Elisei R

International journal of molecular sciences 2021; (22(4)) doi:10.3390/ijms22041726.

Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

Soares P, Póvoa AA, Melo M, et al.

Endocrine pathology 2021; (32(1)):44-62 doi:10.1007/s12022-021-09666-1.

Revised Bethesda System for Reporting Thyroid Cytology: Lessons learned from an appraisal of 5 years of experience in a central hospital.

El Hag IA, Johnston J, Alessa E, Al Shammari M

Cytopathology : official journal of the British Society for Clinical Cytology 2021; (32(4)):482-492 doi:10.1111/cyt.12970.

Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on fine-needle aspiration diagnoses of thyroid nodules.

Chen L, Liu L, Hodjat P, Leng B

Proceedings (Baylor University. Medical Center) 2021; (34(4)):456-459 doi:10.1080/08998280.2021.1889281.

Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis.

Won HR, Jeon E, Chang JW, et al.

Cancers 2022; (14(6)) doi:10.3390/cancers14061470.

Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.

Lam AK

Methods in molecular biology (Clifton, N.J.) 2022; (2534()):109-119 doi:10.1007/978-1-0716-2505-7_8.

Strategies for Radioiodine Treatment: What's New.

Sparano C, Moog S, Hadoux J, et al.

Cancers 2022; (14(15)) doi:10.3390/cancers14153800.

Radioiodine therapy in the different stages of differentiated thyroid cancer.

Valerio L, Maino F, Castagna MG, Pacini F

Best practice & research. Clinical endocrinology & metabolism 2023; (37(1)):101703 doi:10.1016/j.beem.2022.101703.

The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.

Wu J, Hu XY, Ghaznavi S, et al.

Thyroid : official journal of the American Thyroid Association 2022; (32(12)):1509-1518 doi:10.1089/thy.2022.0055.

Cytological Features of "Non-Invasive Follicular Tumour with Papillary like Nuclear Features" - A Single Institutional Experience in India.

Amita K, Rakshitha HB, Sanjay M, Kalappa P

Journal of cytology 2023; (40(1)):28-34 doi:10.4103/joc.joc_192_21.

Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma.

Sgrò D, Brancatella A, Greco G, et al.

The Journal of clinical endocrinology and metabolism 2023; (108(11)):e1186-e1192 doi:10.1210/clinem/dgad313.

Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis.

Yu J, Kaur R, Ayeni FE, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2023; (55(6)):379-387 doi:10.1055/a-2084-3408.

Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah.

Jasim MS, Hussein IH, Alidrisi HA, Mansour AA

Cureus 2023; (15(10)):e47990 doi:10.7759/cureus.47990.

Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer.

Gulec SA, Benites C, Cabanillas ME

Journal of clinical medicine 2024; (13(13)) doi:10.3390/jcm13133645.

The role of the hypothalamic-pituitary-thyroid axis in thyroid cancer.

Abaandou L, Ghosh R, Klubo-Gwiezdzinska J

The lancet. Diabetes & endocrinology 2025; (13(4)):333-346 doi:10.1016/S2213-8587(24)00364-4.

Clinical characteristics, surgical approaches, and prognosis of follicular and papillary thyroid cancer in children and adolescents: a retrospective cohort study.

Liu Y, Meng T, Ma S, et al.

Pediatric surgery international 2025; (41(1)):89 doi:10.1007/s00383-025-05990-3.

Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study.

Yoo J, Kim M, Kim HK, et al.

Endocrine-related cancer 2025; (32(7)).

Laterocervical Lymph Node Metastases in Papillary Thyroid Carcinoma: Predictive Factors for Recurrence and Oncological Outcome.

Migliorelli A, Manuelli M, Tringali AM, et al.

Journal of personalized medicine 2025; (15(10)) doi:10.3390/jpm15100496.

Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms.

Pishdad R, Ahmadi S

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):401-405 doi:10.1016/j.eprac.2025.12.002.

A Qualitative Study of Clinician Barriers and Facilitators to De-escalation of Thyroid Stimulating Hormone Suppression in Thyroid Cancer Survivors.

Francis-Levin N, Tan CY, Gay BL, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):392-400 doi:10.1016/j.eprac.2025.12.009.

Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.

Park H, Kim BR, Yoo JH, et al.

Oral oncology 2026; (175()):107912 doi:10.1016/j.oraloncology.2026.107912.

Neoadjuvant tyrosine kinase inhibitor therapy for locally advanced, well-differentiated thyroid cancer.

Bock R, Arman S, Ardila Pardo GL, et al.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2026; doi:10.1016/j.surge.2026.05.001.

Cell-state transitions and microenvironmental remodeling in thyroid cancer progression revealed by single-cell and spatial transcriptomics.

Wang X, Tao D, Xu J, et al.

Frontiers in immunology 2026; (17()):1904196 doi:10.3389/fimmu.2026.1904196.

Comparison of 2015 and 2025 ATA Risk Stratification Systems for Predicting Recurrence in Papillary Thyroid Carcinoma.

Yoo JH, Lee S, Kim BR, et al.

Annals of surgical oncology 2026; doi:10.1245/s10434-026-20381-1.